Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects-Reference-Cited by-同舟云学术

Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects

Published:2022-04-30 Issue:5 Volume:42 Page:447-458
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Xiang Qian,Liu Zhiyan,Mu Guangyan,Xie Qiufen,Zhang Hanxu,Zhou Shuang,Wang Zining,Guo Ninghong,Huang Jie,Jiang Jie,Li Jian,Yang Guoping,Cui Yimin

Funder

Key Technologies Research and Development Program

National Natural Science Foundation of China

Beijing Municipal Commission of Science and Technology of China Pharmaceutical Innovation Cultivation and Industry Support Platform Capacity Construction Project

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-022-01154-6.pdf

Reference33 articles.

1. Alexopoulos D, Xanthopoulou I, Siapika A, et al. Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients. Int J Cardiol. 2013;168:629–30.

2. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852–6.

3. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514–21.

4. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487–96.

5. Cassese S, Ndrepepa G, Byrne RA, Laugwitz KL, Schunkert H, Fusaro M, et al. Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease: a meta-analysis of randomized clinical trials. Am Heart J. 2020;219:109–16.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome;Clinical Pharmacokinetics;2023-02-03

2. PROK2 , HRNR , and FIG4 as potential genetic biomarkers of high bleeding propensity in East Asian patients with acute coronary syndrome using ticagrelor;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2022-11-02